CREXONT ER
Phase 3Small molecule
CREXONT ER is one of 76 small molecule programs targeting Parkinson disease. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
75
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
91 competitors in Parkinson Disease
#DrugCompanyPhaseTrials
1Aricept
EisaiApproved
Nourianz
Kyowa Kirin Co., Ltd.Approved
Keppra
UCBApproved
Ritalin
NovartisApproved
Epidiolex
Jazz PharmaceuticalsApproved
Dostinex
PfizerApproved
Buspar
Bristol-Myers SquibbApproved
Golytely
BayerApproved
Victoza
Novo NordiskApproved
Actos
TakedaApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Parkinson's Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CREXONT ER. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- TThe Cleveland Clinic